Drug Pricing Activity At US FDA May Be Unique To Gottlieb Tenure
Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
You may also be interested in...
US Energy and Commerce Committee leaders request data on complex generic approvals, guidances, saying additional changes may be needed for faster approvals.
Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.
An eventful year for sweeping drug pricing legislative proposals in the US will end with enactment of a long-standing carryover proposal – new procedures intended to address perceived abuses of the REMS process – but nothing more substantial for the drug industry.